Amanda Peet, Hoda Kotb Share Breast Cancer Survival Stories on TODAY

Amanda Peet and Hoda Kotb spoke about their breast cancer journeys during a live TODAY interview on March 26. Peet appeared to discuss her new film, Fantasy Life, and to address her recent health news.

Peet’s diagnosis and essay

Peet revealed she was diagnosed in the fall of 2025. Doctors identified hormone-receptor-positive, HER2-negative disease.

She wrote a personal essay for The New Yorker describing the diagnosis. Writing helped her process the shock while both parents were in hospice care.

Peet described the act of writing as cathartic and a way to contain the upheaval in her life. She noted her parents were not religious, which shaped her response.

After treatment, Peet received her first clear scan in January 2026. She also disclosed that her cancer is lobular, a less-studied subtype.

Kotb’s perspective and shared conversation

Hoda Kotb, who was diagnosed in 2007, asked Peet what prompted the essay. Kotb has long spoken about her own experience with the disease.

Kotb told Peet that hearing the words “breast cancer” is a life-changing moment. She added that today there is often a clearer path for care and treatment.

In 2024, Kotb reflected on her decision to go public. She said she initially wanted privacy but was encouraged to speak out.

Emotional and practical aftermath

Peet called herself extremely fortunate for financial and caregiving support. She mentioned SAG health insurance, her husband, and a nanny helped her through treatment.

She also acknowledged that many patients lack similar resources. That disparity weighed on her as she considered others’ struggles.

Calls for research

Peet emphasized concern about lobular cancer being understudied. She urged more research into that subtype.

The need for targeted study was a key takeaway from the conversation. Both women highlighted ongoing gaps in knowledge and care.

Filmogaz.com covered the exchange between Amanda Peet and Hoda Kotb on TODAY. The interview blended personal testimony with calls for awareness and research.